Aterovax is an emerging biopharmaceutical company dedicated to one specific target : improving the management of diagnostic, prognosis and treatment of atherosclerosis, main process responsible for important vascular events including coronary artery disease, stroke and peripheral arterial disease.

 

So far, no existing therapy targets directly the atherosclerotic plates. Our ambition is to fulfill this unmet medical need.

 
 
 
Last News
 
ATEROVAX highlighted by the Paris Region Agency
  ATEROVAX, a success story exemple in Paris Region
View    

Pr Alain TEDGUI on France Info, the French National News radio station

 

Pr TEDGUI, interviewed  November, 21st, 2008 presents the huge potential and the impacts of his work  to treat cardiovascular disease.

View    
Aterovax supported by the ANR  
1.450.000,00E financial support its cardiovascular  Immunotherapy program
View    
Siemens rewards Aterovax
Since 2000, Siemens rewards each year one young companies holding innovating project.
View    

  Read more...

© 2008 Aterovax. All Rights Reserved.